CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development in Immuno-Oncology

"Cancer Research Center of Lyon iPS novel PDX models formulate new immune cell focused strategies"

SAN DIEGO, July  19, 2018  (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, is proud to announce the award of its Patient-Derived Xenograft (PDX) grant program to doctors Fabrice Lavial, Christophe Caux and Bertrand Dubois from the Cancer Research Center of Lyon (CRCL).

The grant program was established to support oncology researchers pursuing scientific advancements in cancer using PDX technology. Following an extensive review, CrownBio's Scientific Steering Committee selected Dr. Lavial and his colleagues at the CRCL due to their project's potential to create breakthroughs in preclinical oncology strategies. Their research combines PDX and iPS cell technologies to create patient-specific, humanized models. These unique models will help scientists assess the efficacy of novel immuno-oncology therapeutics, reveal new information about the immune system's involvement in cancer and identify resistance mechanisms to current immunotherapies.

"CrownBio launched our PDX grant program with the goal of accelerating the pace of preclinical innovation to improve clinical predictions with sound science," Dr. Henry Li, SVP Global Scientific Research and Innovation commented. "The CRCL's iPS PDX models exemplify this goal by providing researchers with novel models they can use to formulate new strategies that harness immune cells to treat cancer."

"We believe the cutting-edge research models that will be developed at the CRCL will deepen researchers' understanding of the immune system's role in cancer genesis and progression," said Michael Prosser, VP Corporate Development and Strategy. "Using this knowledge, researchers can make better decisions in drug development and design more effective immunotherapeutics, so we are proud and excited to make CRCL's concept a reality."

About Crown Bioscience

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[e-mail]

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire